USA — CVS Health has set in motion a significant transformation in how it prices prescription drugs, discarding a complex model that has long been criticized for its lack of transparency and contributing to inflated healthcare costs.
The move marks CVS as the latest player aiming to reshape the traditional prescription drug pricing system, a system under intense political scrutiny for years.
The pharmaceutical giant plans to introduce a new reimbursement model for its pharmacies starting January 1, 2025, focusing on commercial payors.
While the impact on prescription drug costs varies, CVS executives assure that their commitment is towards lowering drug pricing and enhancing transparency.
CEO Karen Lynch emphasized this commitment, stating, “What this does is it essentially aligns the economics of our pricing for drugs to what consumers will pay at the pharmacy counter.”
The new model, named CVS CostVantage, seeks to introduce a sustainable and transparent formula for determining medication prices and corresponding pharmacy reimbursements.
CVS pharmacies will be reimbursed based on the drug’s cost, a clearly defined markup, and a fee covering handling and dispensing prescriptions.
This shift aims to replace the current complex reimbursement system that lacks clarity and transparency, often leading to ambiguity surrounding fees and markups.
CVS’s shares surged nearly 4% after unveiling the CVS CostVantage plan, which received positive attention during the company’s investor day. The innovative approach also comes with a better-than-expected 2024 revenue forecast.
This strategy echoes a similar approach taken by billionaire Mark Cuban, who launched an online pharmacy called Cost Plus Drugs last year.
Cuban’s company focuses on driving down medicine prices by applying a fixed 15% markup over the drug’s cost, plus pharmacy fees.
While Cuban has yet to react to CVS’s new model, his venture has already disrupted the healthcare industry, prompting other players like Cigna to adopt a pricing model akin to Cost Plus Drugs.
CVS’s move is not without its challenges, as it navigates increased scrutiny over pharmacy benefit managers’ (PBMs) practices.
PBMs, including CVS Health’s Caremark, have faced criticism for their role in escalating drug costs, prompting regulatory attention from the Federal Trade Commission.
As CVS pioneers a more transparent and consumer-centric approach to drug pricing, the broader healthcare industry is witnessing a shift in how major players operate.
The Biden administration is also taking strides to curb medication prices, as seen in its Inflation Reduction Act, which includes negotiations for the first 10 prescription drugs within the federal Medicare program, aimed at ensuring affordability for older Americans.